Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.
On Feb. 7, 2018, the U.S. FDA approved a new fixed-dose combination (FDC) containing bictegravir, emtricitabine and tenofovir alafenamide (TAF).
Last year's antiretroviral darling was dolutegravir (Tivicay, DTG). Now, the limelight has shifted to its integrase sibling, bictegravir. Requiring no pharmacological boosting, boasting a high barrier to resistance, and in early 2018 available co-for...